GlassScriptPhysician profile
Eman Hazimi
NPI 1811422413
$5,662.67
in general payments reported to CMS, 2019-2025
32 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 86% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,693 · 2022: $830 · 2023: $1,063 · 2024: $996 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,138.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,153.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $995.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $830.10 | 2021-2025 | |
| Novo Nordisk INC | $450.89 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $443.48 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.83 | 2021-2025 | Caplyta |
| Lilly USA, LLC | $220.29 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $213.62 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $146.98 | 2021-2022 | |
| Ucb, INC. | $113.35 | 2021-2025 | Nayzilam |
| Xeris Pharmaceuticals, INC. | $99.47 | 2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $85.63 | 2021-2024 | |
| Amarin Pharma, INC. | $73.25 | 2021 | |
| Merck Sharp & Dohme LLC | $68.27 | 2022-2023 | Verquvo |
| Amgen INC. | $64.38 | 2024 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $57.73 | 2021-2023 | |
| Lundbeck LLC | $43.46 | 2022-2023 | Rexulti |
| Dexcom, INC. | $40.74 | 2021-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $34.24 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $30.80 | 2021 | |
| Tolmar, INC. | $26.87 | 2025 | Jatenzo |
| Antares Pharma, INC. | $25.13 | 2025 | Xyosted |
| Genentech USA, INC. | $17.53 | 2021 | |
| Bausch Health US, LLC | $16.83 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.89 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $15.25 | 2024 | Opsumit, Uptravi |
| Arbor Pharmaceuticals, INC. | $14.93 | 2021 | |
| Abbott Laboratories | $14.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.93 | 2021 | |
| Sanofi Pasteur INC. | $13.34 | 2022 | |
| Evoke Pharma, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Hazimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.